Pierre Aucouturier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10824377/publications.pdf

Version: 2024-02-01

44 papers	3,203 citations	172457 29 h-index	276875 41 g-index
44 all docs	44 docs citations	44 times ranked	2595 citing authors

#	Article	IF	Citations
1	Megalin Knockout Mice as an Animal Model of Low Molecular Weight Proteinuria. American Journal of Pathology, 1999, 155, 1361-1370.	3.8	407
2	Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides. Lancet, The, 2000, 355, 192-197.	13.7	280
3	Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain, 2016, 139, 1237-1251.	7.6	260
4	Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immune-complex glomerulonephritis. Kidney International, 2004, 65, 85-96.	5.2	212
5	Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. Journal of Clinical Investigation, 2001, 108, 703-708.	8.2	152
6	Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney International, 1994, 46, 965-972.	5.2	123
7	Heavy-Chain Deposition Disease. New England Journal of Medicine, 1993, 329, 1389-1393.	27.0	119
8	Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney International, 1995, 48, 72-79.	5.2	112
9	Immunoglobulin Light (Heavy)-Chain Deposition Disease: From Molecular Medicine to Pathophysiology-Driven Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1342-1350.	4.5	109
10	Light Chain Deposition Disease: A Model of Glomerulosclerosis Defined at the Molecular Level. Journal of the American Society of Nephrology: JASN, 2001, 12, 1558-1565.	6.1	103
11	Recurrent Membranous Nephropathy in an Allograft Caused by IgG3Î¹ Targeting the PLA2 Receptor. Journal of the American Society of Nephrology: JASN, 2012, 23, 1949-1954.	6.1	94
12	Heavy chain deposition disease: The disease spectrum. American Journal of Kidney Diseases, 1999, 33, 954-962.	1.9	92
13	Renal Lesions Associated with IgM-Secreting Monoclonal Proliferations. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1339-1349.	4.5	89
14	Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients. American Journal of Kidney Diseases, 2013, 62, 679-690.	1.9	75
15	Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis. Clinical Immunology and Immunopathology, 1988, 46, 186-194.	2.0	73
16	Overrepresentation of the VÏ°IV subgroup in light chain deposition disease. Immunology Letters, 1994, 42, 63-66.	2.5	73
17	Functional Implication of Cellular Prion Protein in Antigen-Driven Interactions between T Cells and Dendritic Cells. Journal of Immunology, 2006, 176, 7254-7262.	0.8	67
18	Unravelling the immunopathological mechanisms of heavy chain deposition disease with implicationsÂfor clinical management. Kidney International, 2017, 91, 423-434.	5.2	66

#	Article	IF	Citations
19	Renal involvement in monoclonal (type I) cryoglobulinemia: Two cases associated with IgG3Î¹ cryoglobulin. American Journal of Kidney Diseases, 2002, 40, 1091-1096.	1.9	65
20	Nodular Glomerulosclerosis with Deposition of Monoclonal Immunoglobulin Heavy Chains Lacking CH1. Journal of the American Society of Nephrology: JASN, 1999, 10, 519-528.	6.1	65
21	In Vivo Depletion of CD11c+ Cells Impairs Scrapie Agent Neuroinvasion from the Intestine. Journal of Immunology, 2007, 179, 7758-7766.	0.8	60
22	Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Engineering, Design and Selection, 1999, 12, 363-369.	2.1	58
23	Impaired Lysosomal Function Underlies Monoclonal Light Chainâ€“Associated Renal Fanconi Syndrome. Journal of the American Society of Nephrology: JASN, 2016, 27, 2049-2061.	6.1	52
24	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	4.8	42
25	Structure of Abnormal Heavy Chains in Human Heavy-chain-deposition Disease. FEBS Journal, 1995, 229, 54-60.	0.2	42
26	Immunoglobulin Î³3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. American Journal of Kidney Diseases, 2004, 43, e2.1-e2.7.	1.9	39
27	The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association. FEBS Journal, 1999, 260, 192-199.	0.2	34
28	Prion Protein Expression by Mouse Dendritic Cells Is Restricted to the Nonplasmacytoid Subsets and Correlates with the Maturation State. Journal of Immunology, 2006, 177, 6137-6142.	0.8	34
29	Biochemical and conformational variability of human prion strains in sporadic Creutzfeldtâ€“Jakob disease. Neuroscience Letters, 1999, 274, 33-36.	2.1	31
30	Immunoglobulin Deposition Disease With a Membranous Pattern and a Circulating Monoclonal Immunoglobulin G With Charge-Dependent Aggregation Properties. American Journal of Kidney Diseases, 2010, 56, 117-121.	1.9	24
31	Monoclonal immunoglobulin deposition disease: A review of immunoglobulin chain alterations. International Journal of Immunopharmacology, 1994, 16, 425-431.	1.1	22
32	MHC-Independent Genetic Factors Control the Magnitude of CD4+ T Cell Responses to Amyloid-Î² Peptide in Mice through Regulatory T Cell-Mediated Inhibition. Journal of Immunology, 2011, 187, 4492-4500.	0.8	19
33	Experimental scrapie in â€˜pltâ€™ mice: an assessment of the role of dendritic-cell migration in the pathogenesis of prion diseases. Journal of General Virology, 2007, 88, 2353-2360.	2.9	18
34	Monoclonal Immunoglobulin Light and Heavy Chain Deposition Diseases: Molecular Models of Common Renal Diseases. Contributions To Nephrology, 2011, 169, 221-231.	1.1	15
35	Th2-polarised PrP-specific Transgenic T-cells Confer Partial Protection against Murine Scrapie. PLoS Pathogens, 2011, 7, e1002216.	4.7	15
36	Structure of Abnormal Heavy Chains in Human Heavy-chain-deposition Disease. FEBS Journal, 1995, 229, 54-60.	0.2	13

#	Article	IF	Citations
37	Adoptive Transfer of T Lymphocytes Sensitized against the Prion Protein Attenuates Prion Invasion in Scrapie-Infected Mice. Journal of Immunology, 2009, 183, 6619-6628.	0.8	13
38	Contribution of Antibody and T Cell-Specific Responses to the Progression of 139A-Scrapie in C57BL/6 Mice Immunized with Prion Protein Peptides. Journal of Immunology, 2008, 181, 768-775.	0.8	11
39	Ig-Related Renal Disease in Lymphoplasmacytic Disorders: An Update. Seminars in Nephrology, 2010, 30, 557-569.	1.6	10
40	A Fresh Perspective on Monoclonal Gammopathies of Renal Significance. Kidney International Reports, 2021, 6, 2059-2065.	0.8	7
41	Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology. Brain, 2017, 140, e39-e39.	7.6	6
42	Renal Amyloidosis and Glomerular Diseases with Monoclonal Immunoglobulin Deposition. , 2010, , 322-334.		2
43	Multiple myeloma with clivus involvement, neurological symptoms, and 45Âg/L proteinorachia. Clinical Case Reports (discontinued), 2020, 8, 5-8.	0.5	0
44	Prion Diseases and the Prion Protein. , 2004, , 376-378.		0